Open Interest and Volume Dynamics
The latest data reveals that Glenmark’s open interest (OI) in derivatives rose sharply from 39,453 contracts to 48,587, an increase of 9,134 contracts. This 23.15% jump is notable given the stock’s underlying value of ₹2,093. The futures segment alone accounted for a value of approximately ₹1,39,223 lakhs, while options contributed a staggering ₹8,862.99 crores, culminating in a total derivatives value of ₹1,40,441.67 lakhs. The volume traded stood at 28,464 contracts, indicating active participation but not an overwhelming surge relative to the OI increase.
Price Performance and Moving Averages
On 24 March 2026, Glenmark’s stock price touched an intraday high of ₹2,137.10, marking a 2.3% rise from previous levels. However, the stock’s day return was a modest 0.24%, underperforming the Pharmaceuticals & Biotechnology sector’s 1.32% gain and the Sensex’s 2.33% advance. The stock trades above its 50-day, 100-day, and 200-day moving averages, signalling a longer-term bullish trend. Yet, it remains below its 5-day and 20-day moving averages, suggesting short-term consolidation or mild weakness.
Investor Participation and Liquidity Considerations
Delivery volume on 23 March was 2.03 lakh shares, a decline of 33.95% compared to the five-day average, indicating reduced investor participation in the cash segment. Despite this, liquidity remains adequate, with the stock’s traded value supporting a trade size of approximately ₹2.8 crore based on 2% of the five-day average traded value. This liquidity profile supports active derivatives trading and allows for sizeable positions without significant market impact.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
Market Positioning and Directional Bets
The sharp rise in open interest, coupled with a moderate volume increase, suggests that market participants are actively repositioning themselves in Glenmark’s derivatives. The increase in OI often reflects fresh capital entering the market or existing traders extending their positions. Given the stock’s mixed technical signals—trading above long-term moving averages but below short-term ones—investors appear to be hedging or speculating on a potential directional move.
Options data, with a total value exceeding ₹8,862 crores, indicates substantial activity in calls and puts, which may be used for directional bets or volatility plays. The futures value of ₹1,39,223 lakhs further underscores the importance of Glenmark in the derivatives market, especially for mid-cap pharmaceutical stocks. The stock’s Mojo Score of 78.0 and a current Mojo Grade of Buy (downgraded from Strong Buy on 6 June 2025) reflect a positive but cautious outlook from fundamental and technical perspectives.
Sector and Market Context
Within the Pharmaceuticals & Biotechnology sector, Glenmark’s underperformance relative to the sector’s 1.32% gain and the Sensex’s 2.33% rise highlights selective investor caution. The sector remains attractive due to ongoing innovation and demand for healthcare products, but individual stock performance can vary based on company-specific news, earnings outlook, and technical factors.
Glenmark’s market capitalisation stands at ₹59,095.67 crore, categorising it as a mid-cap stock. This positioning often attracts a blend of institutional and retail investors, with derivatives activity serving as a key barometer of market sentiment and speculative interest.
Get the full story on Glenmark Pharmaceuticals Ltd.! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology mid-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Implications for Investors
The surge in open interest and active derivatives trading in Glenmark Pharmaceuticals suggests that investors are positioning for potential volatility or directional moves in the near term. While the stock’s long-term technical indicators remain supportive, the short-term underperformance and falling delivery volumes warrant caution.
Investors should closely monitor price action relative to the 5-day and 20-day moving averages, as a sustained break above these could signal renewed momentum. Conversely, failure to hold key support levels may invite further selling pressure. The derivatives market activity provides valuable clues on institutional sentiment and can help gauge the strength of any emerging trend.
Given Glenmark’s Mojo Grade of Buy and a solid Mojo Score of 78.0, the stock remains attractive for investors with a medium-term horizon, especially those comfortable navigating sector-specific risks and market volatility.
Conclusion
Glenmark Pharmaceuticals Ltd. is currently at a pivotal juncture, with a notable increase in open interest signalling heightened market interest and repositioning. Despite short-term underperformance relative to its sector and the broader market, the stock’s fundamentals and mid-cap status continue to attract investor attention. The derivatives market activity offers a window into evolving market sentiment, suggesting that traders are preparing for potential directional moves. Investors should balance these signals with broader sector trends and technical indicators to make informed decisions.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
